SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERN Test

Press Releases

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “Morphometric imaging biomarker identifies Alzheimer's disease even among mixed dementia patients” in Scientific Reports.

“Up until now, there have been no autopsy-validated tests shown to accurately identify AD in the presence of mixed dementia, or dementia from one or more co-existing causes, affecting over half of patients diagnosed with AD,” says Dr. Daniel Alkon, chief scientific advisor, SDx and corresponding author of the paper. “We are pleased to share this groundbreaking data showing that the MI biomarker demonstrated specificity and sensitivity of 100% (p<.001) when compared to the NIH Gold Standard criteria for AD in distinguishing AD from non-AD patients, even in the presence of other co-morbid pathologies.”

Dr. Alkon further explains that DISCERN™ is a CLIA-certified diagnostic skin test comprised of three assays that assess several factors related to synaptic and neuronal loss that impact cognitive loss, as well as regulators of amyloid plaque and neurofibrillary tangles in the brain. The test is autopsy-validated to inform a definitive diagnosis of AD, even in people recently diagnosed with dementia. The DISCERN AD biomarkers also depend on factors that regulate amyloid plaque and tau formation, hallmarks of AD at autopsy.

Additional Info

Media Contact : Michael Tunkelrott

Related Links :

Powered By GrowthZone